FTC Staff Issues FY 2013 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors

In Fiscal Year 2013, companies filed a total of 145 final patent dispute settlements, of which 29 created potential “pay-for-delay” agreements between branded and generic drug companies, according to a new Federal Trade Commission staff report.  Although the number of potential pay-for-delay settlements is down from FY 2012, it is similar to FY 2010 and […]